Table 1.
Baseline demographic and clinical characteristics of patients treated with T-DM1 and patients treated with pertuzumab prior to T-DM1
| Overall population of patients treated with T-DM1 (n = 318) | Patients treated with pertuzumab prior to T-DM1 (n = 184) | |||
|---|---|---|---|---|
| N | % | N | % | |
| Age at T-DM1 treatment (years) | ||||
| Median (min, max) | 58 | (25, 90+) | 57 | (25, 90+) |
| Age group—n (%) | ||||
| < 65 years | 219 | 68.9 | 133 | 72.3 |
| ≥ 65 years | 99 | 31.1 | 51 | 27.7 |
| Race—n (%) | ||||
| Black | 35 | 11.0 | 17 | 9.2 |
| Asian | 17 | 5.3 | 10 | 5.4 |
| Caucasian | 219 | 68.9 | 128 | 69.6 |
| Other | 7 | 2.2 | 3 | 1.6 |
| Not documented | 40 | 12.6 | 26 | 14.1 |
| Practice region—n (%) | ||||
| Midwest | 57 | 17.9 | 41 | 22.3 |
| Northeast | 16 | 5.0 | 7 | 3.8 |
| South | 94 | 29.6 | 46 | 25.0 |
| West | 151 | 47.5 | 90 | 48.9 |
| Stage at initial BC diagnosis—n (%) | ||||
| Stage I | 16 | 5.0 | 9 | 4.9 |
| Stage II | 63 | 19.8 | 44 | 23.9 |
| Stage III | 76 | 23.9 | 48 | 26.1 |
| Stage IV | 115 | 36.2 | 60 | 32.6 |
| Not documented | 48 | 15.1 | 23 | 12.5 |
| Distant metastatic site (at T-DM1 initiation)—n (%) | ||||
| Bone | 184 | 57.9 | 105 | 57.1 |
| Brain | 71 | 22.3 | 38 | 20.7 |
| Liver | 140 | 44.0 | 82 | 44.6 |
| Lung | 127 | 39.9 | 72 | 39.1 |
| Lymph node | 127 | 39.9 | 71 | 38.6 |
| Other | 97 | 30.5 | 55 | 29.9 |
| Not documented | 1 | 0.3 | 1 | 0.5 |
| Number of metastatic organ sites (at T-DM1 initiation)—n (%) | ||||
| Not documented | 1 | 0.3 | 1 | 0.5 |
| 1 | 76 | 23.9 | 43 | 23.4 |
| 2 | 113 | 35.5 | 68 | 37.0 |
| 3+ | 128 | 40.3 | 72 | 39.1 |
| Sites of disease involvement (at T-DM1 initiation)—n (%) | ||||
| Visceral (any metastasis other than bone only) | 297 | 93.4 | 171 | 92.9 |
| Non-visceral (bone only metastasis) | 20 | 6.3 | 12 | 6.5 |
| Not documented | 1 | 0.3 | 1 | 0.5 |
| ECOG PS score (at T-DM1 initiation)—n (%) | ||||
| 0 | 42 | 13.2 | 26 | 14.1 |
| 1 | 199 | 62.6 | 124 | 67.4 |
| ≥ 2 | 45 | 14.1 | 22 | 12.0 |
| Not documented | 32 | 10.1 | 12 | 6.5 |
| Hormone receptor status | ||||
| ER-positive, PR-positive or both (HER2+, HR+) | 203 | 63.8 | 118 | 64.1 |
| ER-negative AND PR-negative (HER2+, HR−) | 113 | 35.5 | 65 | 35.3 |
| Not documented | 2 | 0.6 | 1 | 0.5 |
BC breast cancer, ECOG PS Eastern Cooperative Oncology Group performance status, ER estrogen receptor, HER2+ human epidermal growth factor receptor 2+, HR hormone receptor, max maximum, min minimum, PR progesterone receptor, T-DM1 ado-trastuzumab emtansine